Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights
15 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical...
Global Neurological Therapies Market Research Report 2021: Competitive Landscape and Pipeline Analysis Focusing Specifically on Therapeutic Interventions for Neurodegenerative Diseases
15 nov. 2021 07h08 HE
|
Research and Markets
Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Global Neurological Therapies Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research has identified novel...
Acumen Pharmaceuticals to Present at Upcoming Investor Conferences
08 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
02 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first...
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease
07 oct. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Enrollment of early Alzheimer’s...
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
30 juin 2021 22h44 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a...
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
29 oct. 2020 11h15 HE
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in...
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
29 oct. 2020 07h55 HE
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
26 oct. 2020 07h55 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
22 sept. 2020 07h30 HE
|
Vaccinex, Inc.
Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...